Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label NKTR-102. Show all posts
Showing posts with label NKTR-102. Show all posts
Monday, June 06, 2011

press release: NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®... -- CHICAGO, June 5, 2011 /PRNewswire/ --

›
Note : phase 2, single agent study,  see tables 1-3 for additional information
Sunday, April 24, 2011

press release U.S. - FDA Grants Orphan Drug Designation for Nektar's Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer (NKTR-102)

›
Nektar Therapeutics (Nasdaq: NKTR) today announced that the company's oncology drug candidate, NKTR-102, has been granted orphan drug s...
Monday, June 07, 2010

NKTR-102 Has High Response Rate and Sustained Clinical Benefit in 48 Percent of Women with Platinum-Resistant/Refractory Ovarian Cancer - media

›
Saturday, May 22, 2010

NKTR-102 Phase 2 Clinical Data Accepted for Oral Presentation at 2010 ASCO... -- SAN CARLOS, Calif., May 20 /PRNewswire-FirstCall/ --

›
Nektar To Host Investor Breakfast at ASCO on Monday, June 7, 2010 Nektar will also webcast a presentation to investors and analysts to be ...
Monday, March 08, 2010

Nektar Reports Positive Phase 2 Clinical Data From First Stage Of NKTR-102 Study In Women With Platinum-Resistant Ovarian Cancer - Quick Facts

›
Note: warning on stats in article "The Phase 2 study has now completed enrollment with a total of 71 patients treated. The study is on...